Article

Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jun 2026

Hong S-D, Wang Y-S, Zhao H-Y, Zhao Y-Y, Wang Q-M, Ma Y-X, Li Y-S, Huang Y, Yang Y-P, Fu Z-M, Chen L-K, Zhou F, Yang J, Li X-Y, Hou X, Zhou N-N, Sun L-H, Zhang G-F, Cui J-W, Wu L, Chen G, Zhang Y-X, Wang H-Y, Lv D-Q, Shi J-H, Jiang B, Li C, Li X-L, Tang K-J, Yu Y, Ji Y-H, He Z-Y, Zhu Y, Zhu H, Xiao S, Zhou C-C, Zhang L, Fang W-F